Cisplatin + S-1 + Sunitinib
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stomach Neoplasms
Conditions
Stomach Neoplasms
Trial Timeline
Nov 1, 2007 → Mar 1, 2014
NCT ID
NCT00553696About Cisplatin + S-1 + Sunitinib
Cisplatin + S-1 + Sunitinib is a phase 1 stage product being developed by Pfizer for Stomach Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00553696. Target conditions include Stomach Neoplasms.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00553696 | Phase 1 | Completed |
Competing Products
20 competing products in Stomach Neoplasms